Molecular investigation reveals interleukin 23 pathway dysregulation in pityriasis rubra pilaris, suggesting guselkumab as a potential targeted therapy.
There is no US Food and Drug Administration-approved treatment for pityriasis rubra pilaris (PRP), and it is common for patients to fail to experience improvement with several systemic options. Involvement of interleukin (IL) 23 suggests a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Velasco et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: